1 al inactive disease in patients treated with anti-idiotype antibodies.

2  were treated with 52 courses of custom-made anti-idiotype antibodies.

3 dendritic cells (DCs) pulsed with the murine anti-idiotype antibody 3H1 as a tumor vaccine.

4 s studies suggested that vaccination with an anti-idiotype antibody 3H1, which mimics a specific epit

5 rcinoembryonic antigen (CEA), and that of an anti-idiotype antibody, 3H1, which mimics CEA and can be

6 proach that is analogous to the isolation of anti-idiotype antibodies and were able to isolate peptid

7 se unconfirmed (CR/CRu) to CVP and making an anti-idiotype antibody are 2 independent factors that ea

8                 This material reacts with an anti-idiotype antibody by Western blotting, ELISA, and a

9                              We generated an anti-idiotype antibody, designated CeaVac, that is an in

10  characterize the structural footprint of an anti-idiotype antibody (E1) specific for a potent, fully

11 assay (ELISA) assays for idiotype protein or anti-idiotype antibodies in serum.

12                                              Anti-idiotype antibodies, in addition to cytotoxic T cel

13                           The C3d-conjugated anti-idiotype antibody induces a strong idiotype and ant

14                        We have reported that anti-idiotype antibody response and FcgammaRIIIa 158 val

15 data demonstrate the utility of employing an anti-idiotype antibody to monitor a patient's specific i

16 ound to inhibit mAb HGAC 39.G3 binding to an anti-idiotype antibody with approximately 1000-fold grea